Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: AM281 is a potent and selective central cannabinoid (CB1) receptor antagonist/inverse agonist (Ki =12 nM and 4,200 nM for CB1 and CB2, respectively). Structurally, it is an analog of the CB1 inverse agonist rimonabant . It has no effect on the vanilloid TRPV1 receptor. AM281 has been used to evaluate the potential effects of compounds at CB1. It has also been used to study the membrane localization and cycling of CB1.
AM281 is supplied as a crystalline solid. A stock solution may be made by dissolving the AM281 in the solvent of choice. AM281 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of AM281 in these solvents is approximately 1 mg/ml. AM281 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, AM281 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. AM281 has a solubility of approximately 0.2 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.
Lan, R., Lu, Q., Fan, P., et al. AAPS Pharmsci. 1(3), 1-7 (1999).
Gatley, S.J., Lan, R., Pyatt, B., et al. Life Sci. 61(14), PL-191-PL-197 (1997).
Jerman, J.C., Gray, J., Brough, S.J., et al. Br. J. Anaesth. 89(6), 882-887 (2002).
Baker, C.L. and McDougall, J.J. Br. J. Pharmacol. 142, 1361-1367 (2004).
Brown, I., Cascio, M.G., Wahle, K.W.J., et al. Carcinogenesis 31(9), 1584-1591 (2010).